The stock of BioNTech SE ADR (BNTX) has seen a -8.38% decrease in the past week, with a -7.88% drop in the past month, and a 17.09% flourish in the past quarter. The volatility ratio for the week is 7.11%, and the volatility levels for the past 30 days are at 4.48% for BNTX. The simple moving average for the last 20 days is -6.01% for BNTX’s stock, with a simple moving average of 6.74% for the last 200 days.
Is It Worth Investing in BioNTech SE ADR (NASDAQ: BNTX) Right Now?
BNTX has 36-month beta value of 0.20. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 5 as “overweight,” 7 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNTX is 239.44M, and currently, short sellers hold a 0.84% ratio of that float. The average trading volume of BNTX on November 21, 2024 was 1.06M shares.
BNTX) stock’s latest price update
BioNTech SE ADR (NASDAQ: BNTX)’s stock price has dropped by -4.00 in relation to previous closing price of 106.40. Nevertheless, the company has seen a loss of -8.38% in its stock price over the last five trading days. barrons.com reported 2024-11-19 that Evercore ISI analyst Cory Kasimov upgrades the German drugmaker’s stock to Outperform from In Line.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Evercore ISI repeating the rating for BNTX by listing it as a “Outperform.” The predicted price for BNTX in the upcoming period, according to Evercore ISI is $125 based on the research report published on November 19, 2024 of the current year 2024.
Berenberg, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $130. The rating they have provided for BNTX stocks is “Buy” according to the report published on November 19th, 2024.
Goldman gave a rating of “Buy” to BNTX, setting the target price at $137 in the report published on November 08th of the current year.
BNTX Trading at -10.20% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.32% of loss for the given period.
Volatility was left at 4.48%, however, over the last 30 days, the volatility rate increased by 7.11%, as shares sank -7.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.89% upper at present.
During the last 5 trading sessions, BNTX fell by -8.38%, which changed the moving average for the period of 200-days by +6.40% in comparison to the 20-day moving average, which settled at $108.67. In addition, BioNTech SE ADR saw -3.22% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTX starting from Jeggle Helmut Wolfgang, who proposed sale 150,000 shares at the price of $103.56 back on Nov 15 ’24. After this action, Jeggle Helmut Wolfgang now owns shares of BioNTech SE ADR, valued at $15,534,000 using the latest closing price.
Tureci Ozlem, the Officer of BioNTech SE ADR, proposed sale 556,000 shares at $108.73 during a trade that took place back on Nov 12 ’24, which means that Tureci Ozlem is holding shares at $60,453,880 based on the most recent closing price.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.31 for the present operating margin
- 0.84 for the gross margin
The net margin for BioNTech SE ADR stands at -0.15. The total capital return value is set at -0.05. Equity return is now at value -2.37, with -2.07 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 6.31. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -24.08.
Currently, EBITDA for the company is 1.09 billion with net debt to EBITDA at 25.31. When we switch over and look at the enterprise to sales, we see a ratio of 4.55. The receivables turnover for the company is 2.54for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
To put it simply, BioNTech SE ADR (BNTX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
